The headline reads as positive (76% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › MMSI
Merit Medical Systems Inc (MMSI) stock analysis
BUY 43% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Merit Medical Systems Inc (MMSI) BUY with 43% confidence at a price of $93.39. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$93.39
Technical picture
The 14-day RSI is 68, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.5x the 20-day average).
Fundamentals
The PEG ratio is 1.67, which looks reasonably priced for its growth.
The company reports a profit margin of 9.2% and revenue growth of +9.5%.
In its latest quarter it earned $1.19 per share, which beat the $0.96 analysts expected, with revenue +9.5% year over year.
Wall Street's average rating is 1.9 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $100.67.
Trade plan from the model
The model's long / bullish plan uses an entry near $93.39, a target of $100.67 (+7.8%) and a stop-loss at $88.76 (-5.0%).
That is a reward-to-risk ratio of about 1.6 to 1: the potential gain is larger than the potential loss.
The plan has a time limit: reassess by Nov 19, 2026 whatever the price does.
Entry$93.39
Target$100.67
Stop-loss$88.76
Reassess byNov 19, 2026
Research notes
MMSI’s bull case is accelerating organic growth, stronger margins, cash generation, and continued traction across its therapeutic and foundational platforms; analysts see potential upside toward roughly $100 from the low-$90s. The bear case is that the stock’s premium valuation leaves limited room for execution errors, while tariffs, China weakness, reimbursement uncertainty for WRAPSODY, inventory investment, and ongoing capital spending could pressure cash flow and margins. The major recent catalyst was the October 29 Q3 report: revenue rose 8.4% year over year to $416.2 million, adjusted EPS reached $1.12, and management raised full-year 2026 revenue and adjusted-EPS guidance. Merit’s October 13 acquisition of Solo Pace for about $45 million is an additional portfolio-expansion catalyst, though recent analyst actions included new Hold ratings near $90.
The model's one-paragraph read
Leans BUY — composite score +0.43 (BUY). Technicals: RSI 67.8, MACD bullish, price above SMA50. Fundamentals: PEG 1.67, margin 9.2%, revenue growth 9.5%. Financial results: YoY revenue +9.5%, last EPS surprise +24.0%. FinGPT news read: neutral. Internet research: MMSI’s **bull case** is accelerating organic growth, stronger margins, cash generation, and continued traction across its therapeutic and foundational platforms; analysts see potential upside toward roughly $100 from the low-$90s. The **bear case** is that the stock’s premium valuation leaves limited room for execution errors, while tariffs, China weakness, reimbursement uncertainty for WRAPSODY, inventory investment, and ongoing capital spending could pressure cash flow and margins. The major recent catalyst was the October 29 Q3 report: revenue rose 8.4% year over year to $416.2 million, adjusted EPS reached $1.12, and management raised full-year 2026 revenue and adjusted-EPS guidance. Merit’s October 13 acquisition of Solo Pace for about $45 million is an additional portfolio-expansion catalyst, though recent analyst actions included new Hold ratings near $90. Suggested levels: entry $93.39, target $100.67, stop-loss $88.76, exit by 2026-11-19 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for MMSI
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 43% | $93.39 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on MMSI
Oct 29, 2026 · Merit Medical Misses On Normalized EPS But Raises Guidance A Third Time As 9% Organic Growth Holds; Gross Margin Slippage Is The Crack
- Oct 29, 2026: Merit Medical Misses On Normalized EPS But Raises Guidance A Third Time As 9% Organic Growth Holds; Gross Margin Slippage Is The Crack (Earnings Whispers)
- Oct 29, 2026: Merit Medical: Q3 Earnings Snapshot (Associated Press)
Frequently asked questions
Is MMSI a buy right now?
As of Oct 29, 2026, our automated model rates Merit Medical Systems Inc (MMSI) BUY with 43% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for MMSI?
The model's most recent plan targets $100.67 with a stop-loss at $88.76, from an entry near $93.39.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.